Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Understanding when to shift from stocks to bonds can enhance your investment strategy. Make informed decisions to maximize returns.
22,202 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Savara investors should stay focused on how insider moves and regulatory timelines interact with a growing biotech st...
A major market moment is shaping up as Dan Ives weighs in on SpaceX’s potential public debut. This article breaks dow...
Choosing the right pharmaceutical ETF can feel like balancing income with growth. This guide compares VanEck's PPH an...
For dividend kings long-term investors, a disciplined, income-forward approach can power wealth over two decades. Thi...
Two software leaders, HubSpot and CS Disco, face different AI-driven journeys. This guide breaks down growth, risk, a...
When two tech giants sit in the same valuation neighborhood, smart investors focus on the details. This guide breaks ...
IREN stock fell sharply as investors reprice AI infrastructure bets after a month of steep declines. While the sector...
In a market flooded with hype, even legendary value investors feel the pinch. This guide explains why Warren Buffett ...
Massive AI budgets are on the horizon. This article breaks down who will spend the most, why the opportunity matters,...
In a world of hot bets and fast trades, one blue-chip name stands out as a potential core holding. Learn why Johnson ...
Scorpio Tankers has moved from a debt-laden balance sheet to net cash of roughly $334 million by early 2026, a develo...